Eupraxia Pharmaceuticals Reports Q3 Financial Results with Increased Net Loss
Eupraxia Pharmaceuticals reported a net loss of $15.2 million for the third quarter, representing a significant increase compared to the $6.4 million loss recorded during the same period last year. Despite the widening losses, the company maintains a strong liquidity position. As of September 30, 2026, Eupraxia reported total cash and cash equivalents of $75.2 million, supplemented by $51.2 million in short-term investments. This brings their combined liquidity to $126.4 million. Management stated that these current reserves are expected to provide sufficient funding for operations through the second half of 2028.
Topics: Cash Reserves Financial Reporting Liquidity Net Loss